Abstract Number: 2747 • 2018 ACR/ARHP Annual Meeting
Leflunomide and Methotrexate in Treatment of Giant Cell Arteritis: Comparison of Efficacy, Safety and Drug Survival
Background/Purpose: Methotrexate (MTX) and leflunomide (LEF) are used as adjunct immunosuppressants and corticosteroid sparing agents in treatment of Giant Cell Arteritis (GCA), but the efficacy…Abstract Number: 2991 • 2018 ACR/ARHP Annual Meeting
Malignancies In Giant Cell Arteritis- A Population-Based Cohort Study
Background/Purpose: To investigate the cancer risk in patients with biopsy-proven giant cell arteritis (GCA). Methods: The study population consisted of 830 patients (74 % women)…Abstract Number: 2748 • 2018 ACR/ARHP Annual Meeting
Giant Cell Arteritis in Treatment with Tocilizumab. Evolution of Vascular FDG Uptake on PET/CT
Background/Purpose: Giant cell arteritis (GCA) is a large-vessel vasculitis which can involve the aorta and/or its major branches. Tocilizumab (TCZ) seems to be effective in…Abstract Number: 2995 • 2018 ACR/ARHP Annual Meeting
Healthcare Cost of Potential Glucocorticoid-Associated Adverse Events in Patients with Giant Cell Arteritis
Background/Purpose: To quantify the healthcare expenditures associated with oral glucocorticoids-related-adverse events (OGCs-AEs), among patients in the US with giant cell arteritis (GCA) using claims data…Abstract Number: 2753 • 2018 ACR/ARHP Annual Meeting
Extension of Extracranial Vessel Involvement in Patients with Giant Cell Arteritis
Background/Purpose: Giant cell arteritis (GCA) is a large vessel vasculitis with a predisposition for the cranial branches of the external carotid artery. However, aorta and…Abstract Number: 2754 • 2018 ACR/ARHP Annual Meeting
Comparison between Tocilizumab Prescribed As Monotherapy Versus Combined with Conventional Immunosuppressant Agents in Giant Cell Arteritis Patients
Background/Purpose: Giant cell arteritis (GCA) can be refractory to corticosteroid therapy (1-3). Tocilizumab (TCZ) has been approved in the treatment of GCA. There are no…Abstract Number: 783 • 2017 ACR/ARHP Annual Meeting
European League Against Rheumatisms Recommendations for the Use of Imaging in Large Vessel Vasculitis in Clinical Practice
Background/Purpose: Modern imaging modalities including ultrasound, magnetic resonance imaging (MRI), computed tomography (CT) and 18F-FDG positron emission tomography (PET/CT) have been increasingly used in primary…Abstract Number: 823 • 2017 ACR/ARHP Annual Meeting
Seasonal Variation in Giant Cell Arteritis and Polymyalgia Rheumatica Hospitalizations: Data from Nationwide Inpatient Sample
Background/Purpose: Most studies looking at seasonal variations in giant cell arteritis (GCA) note a seasonal trend, but show disparity on timing. Concurrent peaks of GCA…Abstract Number: 786 • 2017 ACR/ARHP Annual Meeting
Smoking As a Risk Factor for Giant Cell Arteritis: A Systematic Review and Meta-Analysis
Background/Purpose: Tobacco smoking is a well-established risk factor for the development of several autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. A similar…Abstract Number: 892 • 2017 ACR/ARHP Annual Meeting
Health-Related Quality of Life in Patients with Giant Cell Arteritis Treated with Tocilizumab in a Randomized Controlled Phase 3 Trial
Background/Purpose: Superior rates of sustained glucocorticoid (GC)–free remission were shown in patients with giant cell arteritis (GCA) treated with weekly (QW) or every-other-week (Q2W) subcutaneous…Abstract Number: 787 • 2017 ACR/ARHP Annual Meeting
Prevalence of Relapses of Giant Cell Arteritis in Patients Treated with Corticosteroids: A Meta-Analysis
Background/Purpose: The relapse rate of giant cell arteritis (GCA) in the patients treated by corticosteroids (CS) varied widely in observational series and randomized trials. The…Abstract Number: 1734 • 2017 ACR/ARHP Annual Meeting
CXCR5+ CD4 T Cells Signature Differentiates Takayasu Arteritis from Giant Cell Arteritis
Background/Purpose: To compare microarray gene analysis of patients with Giant cell arteritis to patients with Takayasu arteritis. Methods: We performed comparative microarray gene analysis of…Abstract Number: 790 • 2017 ACR/ARHP Annual Meeting
Pre-Clinical Evidences of Immunomodulatory Activities of Tuftsin-Phosphorylcholine on Samples from Patients with Giant Cell Arteritis in Comparison to Corticosteroids
Background/Purpose: Tuftsin-PhosphorylCholine (TPC) is a novel bi-specific molecule which has shown immunomodulatory effects in experimental mouse models of lupus, colitis and arthritis but data in…Abstract Number: 2932 • 2017 ACR/ARHP Annual Meeting
mTOR Pathway Is Activated in Endothelial Cells from Patients with Takayasu Arteritis and Is Modulated By Serum IgG
Background/Purpose: Takayasu arteritis (TA) and giant cell arteritis (GCA) are large-vessel vasculitis characterized by vascular remodelling involving endothelial cells (ECs) and vascular smooth muscle cells,…Abstract Number: 791 • 2017 ACR/ARHP Annual Meeting
Aortic Dilatation in Patients with Large Vessel Vasculitis: A Longitudinal Case Control Study Using Positron Emission Tomography/Computed Tomography
Background/Purpose: To evaluate aortic diameter and predictors of aortic dilatation using FDG-PET/CT in a longitudinally followed cohort of patients with large vessel vasculitis (LVV) compared…
- « Previous Page
- 1
- …
- 22
- 23
- 24
- 25
- 26
- …
- 32
- Next Page »